Zim Laboratories Limited

NSE:ZIMLAB India Drug Manufacturers - Specialty & Generic
Market Cap
$37.92 Million
₹3.28 Billion INR
Market Cap Rank
#28407 Global
#1535 in India
Share Price
₹67.39
Change (1 day)
-3.99%
52-Week Range
₹64.06 - ₹120.82
All Time High
₹149.00
Categories
Companies in India Drug Manufacturers - Specialty & Generic
About

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more

Zim Laboratories Limited (ZIMLAB) - Net Assets

Latest net assets as of September 2025: ₹2.51 Billion INR

Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has net assets worth ₹2.51 Billion INR as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹4.70 Billion) and total liabilities (₹2.19 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₹2.51 Billion
% of Total Assets 53.46%
Annual Growth Rate 7.42%
5-Year Change 56.91%
10-Year Change 156.5%
Growth Volatility 9.85

Zim Laboratories Limited - Net Assets Trend (2013–2025)

This chart illustrates how Zim Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zim Laboratories Limited (2013–2025)

The table below shows the annual net assets of Zim Laboratories Limited from 2013 to 2025.

Year Net Assets Change
2025-03-31 ₹2.52 Billion +5.65%
2024-03-31 ₹2.39 Billion +19.17%
2023-03-31 ₹2.00 Billion +14.02%
2022-03-31 ₹1.76 Billion +9.31%
2021-03-31 ₹1.61 Billion +4.50%
2020-03-31 ₹1.54 Billion +1.79%
2019-03-31 ₹1.51 Billion +10.63%
2018-03-31 ₹1.37 Billion +15.44%
2017-03-31 ₹1.18 Billion +20.33%
2016-03-31 ₹983.37 Million +4.38%
2015-03-31 ₹942.10 Million -18.80%
2014-03-31 ₹1.16 Billion +8.62%
2013-03-31 ₹1.07 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Zim Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 232.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings ₹1.69 Billion 67.02%
Common Stock ₹487.26 Million 19.32%
Other Comprehensive Income ₹264.24 Million 10.48%
Other Components ₹80.30 Million 3.18%
Total Equity ₹2.52 Billion 100.00%

Zim Laboratories Limited Competitors by Market Cap

The table below lists competitors of Zim Laboratories Limited ranked by their market capitalization.

Company Market Cap
SRG HOUSING FINANCE ORD (BSE)
NSE:SRGHFL
 		$10.27 Million
EnBio Co. Ltd.
KQ:352940
 		$10.27 Million
Intelligent Group Limited Ordinary Shares
NASDAQ:INTJ
 		$10.27 Million
elumeo SE
XETRA:ELB
 		$10.27 Million
LUDWIG BECK am Rathauseck - Textilhaus Feldmeier AG
XETRA:ECK
 		$10.27 Million
Toro Energy Limited
PINK:TOEYF
 		$10.26 Million
Cresud S.A.C.I.F. y A. Warrant
NASDAQ:CRESW
 		$10.26 Million
LEFORM
KLSE:0266
 		$10.26 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zim Laboratories Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,387,458,000 to 2,522,375,000, a change of 134,917,000 (5.7%).
  • Net income of 121,652,000 contributed positively to equity growth.
  • Dividend payments of 569,000 reduced retained earnings.
  • Other comprehensive income increased equity by 29,266,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₹121.65 Million +4.82%
Dividends Paid ₹569.00K -0.02%
Other Comprehensive Income ₹29.27 Million +1.16%
Other Changes ₹-15.43 Million -0.61%
Total Change ₹- 5.65%

Book Value vs Market Value Analysis

This analysis compares Zim Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.30x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.61x to 1.30x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-03-31 ₹25.83 ₹67.39 x
2014-03-31 ₹24.18 ₹67.39 x
2015-03-31 ₹19.37 ₹67.39 x
2016-03-31 ₹20.22 ₹67.39 x
2017-03-31 ₹24.33 ₹67.39 x
2018-03-31 ₹28.08 ₹67.39 x
2019-03-31 ₹31.03 ₹67.39 x
2020-03-31 ₹31.59 ₹67.39 x
2021-03-31 ₹33.02 ₹67.39 x
2022-03-31 ₹36.06 ₹67.39 x
2023-03-31 ₹41.12 ₹67.39 x
2024-03-31 ₹49.00 ₹67.39 x
2025-03-31 ₹51.84 ₹67.39 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zim Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.82%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.25%
  • • Asset Turnover: 0.79x
  • • Equity Multiplier: 1.87x
  • Recent ROE (4.82%) is below the historical average (6.07%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 8.92% 5.15% 0.85x 2.04x ₹-11.57 Million
2014 8.74% 4.47% 0.86x 2.27x ₹-14.62 Million
2015 -22.94% -8.25% 0.99x 2.81x ₹-310.29 Million
2016 5.18% 1.93% 1.03x 2.60x ₹-47.36 Million
2017 15.71% 8.10% 0.89x 2.19x ₹67.53 Million
2018 13.99% 7.19% 0.89x 2.18x ₹54.50 Million
2019 10.15% 4.70% 0.99x 2.17x ₹2.30 Million
2020 2.14% 1.26% 0.80x 2.11x ₹-120.86 Million
2021 4.55% 2.38% 0.95x 2.02x ₹-87.58 Million
2022 8.28% 4.40% 0.97x 1.94x ₹-30.21 Million
2023 12.20% 6.13% 1.17x 1.70x ₹44.00 Million
2024 7.22% 4.69% 0.82x 1.87x ₹-66.28 Million
2025 4.82% 3.25% 0.79x 1.87x ₹-130.59 Million

Industry Comparison

This section compares Zim Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $12,445,167,922
  • Average return on equity (ROE) among peers: 14.66%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zim Laboratories Limited (ZIMLAB) ₹2.51 Billion 8.92% 0.87x $10.27 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) $802.45 Million 7.70% 1.12x $12.11 Million
Aarti Drugs Limited (AARTIDRUGS) $1.12 Billion 12.32% 2.74x $152.86 Million
Abbott India Limited (ABBOTINDIA) $42.33 Billion 33.41% 0.40x $1.58 Billion
Ajanta Pharma Limited (AJANTPHARM) $15.68 Billion 32.33% 0.16x $1.48 Billion
Akums Drugs and Pharmaceutical (AKUMS) $7.20 Billion -0.56% 3.88x $128.49 Million
Albert David Limited (ALBERTDAVD) $2.44 Billion 9.06% 0.40x $15.92 Million
Alivus Life Sciences Limited (ALIVUS) $28.17 Billion 17.24% 0.21x $335.22 Million
Alkem Laboratories Limited (ALKEM) $23.74 Billion 20.90% 0.71x $2.42 Billion
Alpa Laboratories Limited (ALPA) $56.73 Million 0.53% 2.47x $5.57 Million
Amrutanjan Health Care Limited (AMRUTANJAN) $2.91 Billion 13.70% 0.25x $77.61 Million